Mathematical Modeling Insights into Improving CAR T cell Therapy for Solid Tumors: Antigen Heterogeneity and Bystander Effects

TL;DR

This paper develops a mathematical model to understand how antigen heterogeneity and bystander effects influence the success of CAR T-cell therapy in solid tumors, aiming to improve treatment strategies.

Contribution

It introduces a new mathematical model incorporating antigen heterogeneity and bystander effects, providing insights into enhancing CAR T-cell therapy for solid tumors.

Findings

Bystander effects can significantly improve therapy efficacy.

Antigen heterogeneity reduces CAR T-cell effectiveness.

Strategies to enhance bystander effects increase tumor cell killing.

Abstract

As an adoptive cellular therapy, Chimeric Antigen Receptor T-cell (CAR T-cell) therapy has shown remarkable success in hematological malignancies, but only limited efficacy against solid tumors. Compared with blood cancers, solid tumors present a unique set of challenges that ultimately neutralize the function of CAR T-cells. One such barrier is antigen heterogeneity - variability in the expression of the antigen on tumor cells. Success of CAR T-cell therapy in solid tumors is unlikely unless almost all the tumor cells express the specific antigen that CAR T-cells target. A critical question for solving the heterogeneity problem is whether CAR T therapy induces bystander effects, such as antigen spreading. Antigen spreading occurs when CAR T-cells activate other endogenous antitumor CD8 T cells against antigens that were not originally targeted. In this work, we develop a mathematical model of CAR T-cell therapy for solid tumors that takes into consideration both antigen heterogeneity and bystander effects. Our model is based on in vivo treatment data that includes a mixture of target antigen-positive and target antigen-negative tumor cells. We use our model to simulate large cohorts of virtual patients to gain a better understanding of the relationship between bystander killing. We also investigate several strategies for enhancing the bystander effect and thus increasing the overall efficacy of CAR T-cell therapy for solid tumor.